Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment. - Schoettler ML; Cheng G; Higham CS; Dvorak CC; Rush C; Rangarajan HG; Al-Nazer M; Polishchuk V; Chaudhury S; Lehmann L; Duncan C; Nishitani M; et al. (Transplantation and cellular therapy, 2026)